Effects of intravitreal Bevacizumab (Avastin) monotherapy in central retinal vein occlusion in young subjects
The current study showed that intravitreal Bevacizumab at a dose of 1.25 mg and with strict control of systemic contributory parameters seemed to improve BCVA and CMT and macular edema measured at baseline to 3 months and 6 months follow-up after three consecutive monthly injections.
Authors
- Undrakonda Vivekanand (ORCID: https://orcid.org/0000-0003-2967-1708)
- Geover Joslen Lobo
- Sarita Lobo
Institutions
- Father Muller Medical College Hospital (IN)
Publication Details
- Journal
- Romanian Journal of Ophthalmology
- Published
- 2024-10-07
- DOI
- https://doi.org/10.22336/rjo.2024.51
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00